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Abstract  
Inhibition of the PARP superfamily tankyrase enzymes suppresses Wnt/b-catenin 
signalling in tumour cells. Here, we describe here a novel, drug-like small molecule 
inhibitor of tankyrase MSC2504877 that inhibits the growth of APC mutant colorectal 
tumour cells. Parallel siRNA and drug sensitivity screens showed that the clinical CDK4/6 
inhibitor palbociclib, causes enhanced sensitivity to MSC2504877. This tankyrase 
inhibitor-CDK4/6 inhibitor combinatorial effect is not limited to palbociclib and 
MSC2504877 and is elicited with other CDK4/6 inhibitors and toolbox tankyrase inhibitors. 
The addition of MSC2504877 to palbociclib enhances G1 cell cycle arrest and cellular 
senescence in tumour cells. MSC2504877 exposure suppresses the upregulation of 
Cyclin D2 and Cyclin E2 caused by palbociclib and enhances the suppression of 
phospho-Rb, providing a mechanistic explanation for these effects. The combination of 
MSC2504877 and palbociclib was also effective in suppressing the cellular 
hyperproliferative phenotype seen in Apc defective intestinal stem cells in vivo. However, 
the presence of an oncogenic Kras p.G12D mutation in mice reversed the effects of the 
MSC2504877/palbociclib combination, suggesting one molecular route that could lead to 
drug resistance. 
Keywords 
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Introduction  
 
Poly(ADP-ribose) polymerases (PARP) family enzymes use b-NAD+ to catalyze the 
synthesis of poly(ADP-ribose) chains on target proteins as a form of post-translational 
modification, known as PARylation1. PARP enzymes regulate a wide range of cellular 
functions, including roles for PARP1 and PARP2 in DNA repair and roles for PARP5A 
and PARP5B, also known as Tankyrase 1 and Tankyrase 2 (TNKS1,2, collectively termed 
tankyrases), in telomere maintenance, the control of mitosis and the regulation of Wnt 
signaling1. Exploiting these roles in the development of novel therapeutic approaches to 
cancer has thus far largely been driven through the discovery and clinical development 
of small molecule PARP1 and PARP2 inhibitors, which have recently been approved for 
the treatment of BRCA1 or BRCA2 mutant ovarian and breast cancers2. In addition, the 
demonstration that experimental “toolbox” tankyrase inhibitors can inhibit oncogenic Wnt 
signaling in colorectal tumour cells3 has driven the discovery of additional, drug-like, 
tankyrase inhibitors that could be used to target tumours that have constitutively active 
Wnt signaling, such as those with premature truncating mutations in the APC tumour 
suppressor protein4. 
 
Tankyrases regulate canonical Wnt signaling via PARylation of AXIN, a critical member 
of a multicomponent protein complex including APC, that controls the concentration of β-
catenin, a key mediator of Wnt signaling. The tankyrase dependent PARylation of AXIN1 
causes AXIN ubiquitination via RNF146, and its eventual proteosomal degradation. This 
reduction in AXIN concentration impairs the activity of the β-catenin destruction complex 
and thus enhances Wnt signaling3. Consistent with this role for tankyrases in Wnt 
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signaling regulation, small molecule inhibitors of tankyrase which impair PARylation 
activity by competing with b-NAD+ for tankyrase binding, reduce AXIN PARylation, 
stabilise the β-catenin destruction complex and thus inhibit Wnt signaling, even in tumour 
cells with APC mutations that otherwise have constitutive Wnt activity3. As well as 
controlling Wnt signaling, tankyrases have also been implicated in the control of Hippo 
signaling by modulating YAP5 an oncoprotein over-expressed in many cancers, which 
when activated binds to transcription factors including p736 and Runx27 .  
 
The significant potential of being able to target a relatively common oncogenic process 
such as Wnt signalling has led to considerable efforts to discover small molecule inhibitors 
that target tankyrase. These include XAV9393, IWR-1 and IWR-28, JW749, JW5510, 
WIKI411, K-75612, the ICR series13 , NVP-TNKS65614 and G007-LK15. Each of these 
inhibitors have been shown to impair Wnt signalling in vitro, and in some cases, elicit anti-
tumour efficacy in xenograft and/or genetically engineered mouse models of cancer15. 
For example, NVP-TNKS656, a modification of XAV939, impairs the growth of Wnt-
dependent lesions in the MMTV-Wnt1 mouse cancer model14,16, JW74 reduces tumour 
burden in the ApcMin mouse tumour model9 and JW55 impairs the proliferation of intestinal 
stem cells with Apc mutations in mice10. Likewise, G007-LK (a JW74 derivative), impairs 
in situ colorectal tumours in mice as well as APC mutant human tumour cell xenografts 
transplanted into recipient animals15. However, in most cases, when used as single 
agents (i.e. not in combination regimens), even when at relatively high-concentrations, 
tankyrase inhibitors appear to only partially impair tumour growth. Furthermore, the 
elevated doses of tankyrase inhibitors required to elicit tumour inhibition often result in 
Tankyrase inhibitor/CDK4,6 inhibitor combination  5 
 
intestinal toxicity, weight loss and death in rodents15,17. This suggests that the use of 
tankyrase inhibitors in appropriate combination treatment regimens might be more 
appropriate as these might allow reduced doses of tankyrase inhibitors to elicit anti-
tumour responses or even enhance the anti-tumour effects of additional agents. For 
example, in vitro studies have demonstrated that tankyrase inhibitors can potentiate 
colorectal tumour cell responses to PI3-Kinase/AKT pathway inhibitors18 or MAP-kinase 
pathway (MEK) inhibitors19, suggesting that additional combination approaches involving 
tankyrase inhibitors might be of some value. 
 
Here, we describe the characterisation of a novel small molecule selective tankyrase 
inhibitor, MSC2504877. This selective agent effectively suppresses Wnt signaling, but 
like previously identified tankyrase inhibitors, has limited effectiveness when used as a 
single agent. In order to understand how MSC2504877 might be used in drug 
combinations, we used parallel in vitro RNA interference and drug sensitivity 
chemosensitisation screens to identify how the tumour cell response to MSC2504877 
might be enhanced. This approach identified multiple different components of the 
canonical Wnt pathway that modulate the response to single agent tankyrase inhibitor 
exposure as well as demonstrating that MSC2504877 can enhance tumour cell 
responses to inhibitors of the G1 restriction point kinases CDK4 and CDK6, including the 
licensed cancer drug palbociclib.  
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Materials and Methods 
Cell lines and cell viability assays. Cell lines were purchased from ATCC, with the 
exception of MCF10A APC mutant isogenic cells (Sigma), and were cultured according 
to the supplier’s instructions. STR typing of 10 loci was performed on each cell line using 
the GenePrint 10 system (Promega) and used to confirm the identity of cell lines prior to 
storage. For short term cell survival assays, 500 cells were plated in media containing 
0.5% (v/v) fetal calf serum in each well of 384 well plates. 24 hrs later, media was changed 
to media containing small molecule inhibitors. Cells were then continuously cultured in 
the presence of small molecule inhibitors for a subsequent five days, at which point cell 
viability was estimated by the use of CellTiter-Glo® Luminescent Cell Viability reagent 
(Promega, used according to the Manufacturer’s instructions). For 14-day drug exposure 
assays, cells were plated in six well plates (500 cells per well).  24 hrs later, media was 
changed to media containing small molecule inhibitors; this media was changed every 
three days, replenishing small molecule inhibitor each time. Cells were continuously 
cultured for 14 days at which point cells were lysed by adding a covering volume of 
CellTiter-Glo® Luminescent Cell Viability reagent (CTG). CTG was then transferred to 
white 96 well plates for luminescent measurements as per the Manufacturer’s 
instructions. CTG readings were normalised to values derived from cells exposed to the 
drug vehicle, DMSO, generating Surviving Fractions (SFs). SF were used to generate 
four parameter dose response curves in Prism (Graphpad).  
 
Biochemical assessment of tankyrase activity by ELISA (Autoparylation assay).  
For analysis of TNKS1 and 2 autoparylation and its inhibition by small molecule inhibitors, 
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an ELISA assay was used. These were performed in 384 well Glutathione coated 
microtiter plates (Express capture Glutathione coated plate, Biocat, Heidelberg, 
Germany). Plates were pre-equilibrated with PBS and then incubated with 50 µl of 20 
ng/well GST-tagged Tnks-1 (1023-1327 aa, prepared in-house) or GST-tagged Tnks-2 
(873-1166 aa, prepared in-house) which was resuspended in assay buffer (50 mM 
HEPES, 4 mM Mg-chloride, 0.05 % (v/v) Pluronic F-68, 2 mM DTT, pH 7.7). This 
incubation was performed overnight at 4°C. Plates were then incubated at room 
temperature for 20 minutes with 50 µl blocking buffer: 0.05 % (v/v) Tween-20, 0.5 % (w/v) 
BSA in PBS. Plates were then washed three times with PBS-Tween-20. The PARylation 
reaction was performed in the presence/absence of tankyrase inhibitors in 50 µl reaction 
solution: 50 mM HEPES, 4 mM Mg-chloride, 0.05 % (v/v) Pluronic F-68, 1.4 mM DTT, 0.5 
% (v/v) DMSO, pH 7.7 + 10 µM bio-NAD (Biolog, Life science Inst., Bremen, Germany) 
for 1 hour at 30°C. The reaction was stopped by washing plates three times with PBS-
Tween-20. For PAR detection, plates were incubated for 30 minutes at room temperature, 
with 50 µl per well of 20 ng/µl Streptavidin, HRP conjugate (MoBiTec, Göttingen, 
Germany) resuspended in PBS + 0.05% (v/v) Tween-20 + 0.01% (w/v) BSA. After 
washing three times with PBS-Tween-20, 50 µl of SuperSignal ELISA Femto Maximum 
sensitivity substrate solution (ThermoFisherScientific (Pierce), Bonn, Germany) was 
added to each well. Following a one-minute incubation at room temperature, 
luminescence signals (700 nm) were measured with an Envision multimode reader 
(Perkin Elmer LAS Germany GmbH). The full value used was the inhibitor-free reaction. 
The pharmacological zero value used was XAV-939 (Tocris) used at a final concentration 
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of 5 µM. The inhibitory values (IC50) were determined using either the program Symyx 
Assay Explorer® or Condosseo® from GeneData.  
 
TNKS, AXIN2 ELISA.  Luminex-based bead assays were employed to assess the level 
of TNKS and AXIN2 proteins in cell and ex vivo xenograft lysates. For detection of TNKS, 
a RIPA cell lysis buffer (10mM Tris HCl, 150mM sodium chloride, 1% NP40, 1% Triton X-
100, 0,4% Na-Deoxycholat, 2mM EDTA, 0,3% SDS) was used and TNKS protein was 
isolated from lysates by incubation with a monoclonal anti-TNKS antibody (Thermo 
Scientific, MA1-41011) bound to fluorescent carboxybeads. Detection of TNKS was 
achieved with a polyclonal anti-TNKS antibody (Santa Cruz, sc-8337) and an appropriate 
PE-fluorescent secondary antibody. An NP40 cell lysis buffer (20mM Tris/HCl pH 8.0, 
150mM NaCl, 1% (v/v) NP40, 10% (v/v) Glycerol) was used for detection of AXIN2. A 
monoclonal AXIN2 antibody (R&D Systems #MAB6078) bound to fluorescent 
carboxybeads was used for isolation of AXIN2 from lysates. A polyclonal anti-AXIN2 
antibody (Cell Signaling #2151) and an appropriate PE-fluorescent secondary antibody 
was used for detection. The amount of isolated TNKS and AXIN2 proteins were 
determined with a Luminex200 device (Luminex Corporation) according to the 
manufacturer’s instruction by counting 100 events per sample.  
 
High-throughput siRNA and small molecule inhibitor screening.  To optimise 
experimental conditions for siRNA screening, we assessed the effectiveness of different 
transfection reagents and selected conditions that met the following criteria: (i) compared 
to a mock control (no lipid or siRNA), the transfection of non-silencing negative control 
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siRNA caused no more than 20 % cell inhibition; (ii) compared to non-silencing negative 
control siRNA, the transfection of PLK1–targeting siRNA caused more than 80% cell 
inhibition; (iii) cell confluency reached 70% within the range of 4-7 days. The later criteria 
allowed assays to be terminated whilst cells were in growth phase. Once optimal 
conditions had been established, COLO320DM cells were transfected with a Dharmacon 
SMARTpool 384-well plate-arrayed siRNA library designed to target 714 kinases and 
kinase-related genes, 320 Wnt pathway–associated genes, 80 tumor suppressor genes, 
and 480 genes recurrently altered in human cancers, as described in 20. Positive control 
(siPLK1) and multiple negative controls (siCON1 and siCON2; Dharmacon, catalog 
numbers D-001210-01-20 and D-001206-14-20, and AllStar; QIAGEN, catalog number 
1027281) were included on every plate. Twenty-four hours after transfection, cell culture 
media containing MSC2504877 (final concentration 0.5 µM) or the drug vehicle was 
added to cells. Cells were then cultured for five additional days, at which point cell viability 
was estimated using CellTiter-Glo assay (Promega). Luminescence values were 
processed using the cellHTS2 R package 21.  To evaluate the effect of each siRNA pool 
on cell viability, luminescence measurements from cells that were exposed to the drug 
vehicle DMSO were log2 transformed, and then centred to the median value for each 
plate. Plate-centred data was then scaled to the median absolute deviation (MAD) and 
median of the library as a whole to produce robust Z-scores. To estimate the effect of 
each siRNA on MSC2504877 sensitisation, luminescence measurements from cells that 
were exposed to the MSC2504877were log2 transformed, and then centred to the median 
value for each plate. Plate centered data for cells exposed to MSC2504877 was then 
normalised according to plate centered data for cells exposed to DMSO, generating a 
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Drug Sensitisation score for each siRNA. DE values were then scaled to the median 
absolute deviation (MAD) and median of the library as a whole to produce robust Z-
scores, as described previously22. All screens were performed in triplicate. Screens 
judged to have poor dynamic range (Z’ factor ≤ 0)23 or poorly correlated replicates (r ≤ 
0.7) were excluded during an evaluation of screen quality.  
 
For small molecule screens, cells were plated in 384 well-plates as above. Twenty-four 
hours later, cell culture media containing the small molecule inhibitor library plus 
MSC2504877 or the drug vehicle, DMSO, was added to cells. Each small molecule 
inhibitor was present at eight different concentrations (0.5, 1, 5, 10, 50, 100, 500 and 1000 
nM). Cells were then cultured for five additional days, at which point cell viability was 
estimated using CellTiter-Glo assay (Promega). Luminescence values were processed 
as described above to produce Drug Sensitisation Z scores for each small molecule 
inhibitor concentration included in the drug library.  
 
Drug synergy estimation. MacSynergyII24 was used to estimate synergy volumes, using 
data from five day drug exposure experiments, as described above.  
 
Western blotting.  Whole cell protein lysates were generated by lysis with NP250 buffer 
(20 mM Tris pH 7.6, 1 mM EDTA, 0.5% NP40, 235 mM NaCl). Following a 20-minute 
incubation at 40C, the lysates were centrifuged and the supernatants were collected. 
Lysates were electrophoresed using Novex precast Bis-Tris gels (Invitrogen) and 
Western blotted on nitrocellulose membranes. Membranes were immunoblotted at 40C 
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overnight using an anti-Rb1 antibody (NEB #9309) diluted 1:1000 (v/v). After washing, 
membranes were then immunoblotted for 1 hour at room temperature with a secondary 
antibody (Li-COR, 926-32210) diluted 1:10,000 (v/v) in 5% (w/v) milk. Protein bands were 
visualised and quantified using the Odyssey FC imaging system and ImageStudio 
software (Li-COR). 
 
Genetically engineered mice. All in vivo experiments were performed in accordance 
with UK Home Office guidelines (Licence 70/8646), and are subject to ethical review by 
the University of Glasgow. The alleles used in this study were Villin-CreERT2 25, Apcfl 26 
and KrasLSL-G12D  27. In the context of Villin-CreERT2; Apcfl/fl experiments, recombination was 
induced through a single intraperitoneal injection of tamoxifen at 80mgkg-1 on two 
consecutive days, while in Villin-CreERT2; Apcfl/fl; KrasLSL-G12D/+ experiments, 
recombination was induced with intraperitoneal injection of 80mgkg-1 tamoxifen on a 
single occasion. In both experimental settings, pharmacological intervention began 24 
hours post initial induction, with palbociclib formulated in a solution of sodium lactate (pH 
4) in H2O, and MSC2504877 formulated in a solution of 0.5% methycellulose in H2O, with 
each respectively administered by oral gavage once or twice daily at the appropriate 
dose.  For analysis of cellular proliferation, 250ul of 5-bromo-2’-deoxyuridine (BrdU) 
(Amersham) was administered by intraperitoneal injection at 2hrs prior to sampling. 
 
Immunohistochemistry/RNAscope. Immunohistochemistry or RNA in situ hybridisation 
was performed throughout this study using formalin fixed paraffin embedded tissue 
specimens and standard protocols.  Primary antibodies used for immunohistochemistry 
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in relation to this study were α-BrdU (BD Biosciences #347580, 1:200) and α-p21CIP/WAF 
(HUGO-291, CNIO, Madrid). RNA in situ hybridisation (RNAscope, Advanced Cell 
Diagnostics Ltd.) was used to detect expression of Lgr5 mRNA in tissue specimens using 
the RNAscope 2.5 LS detection reagent according to manufacturers’ instructions. 
 
Xenograft tumour model. For the in vivo PD study, animal procedures were performed 
in accordance with the German Laws for Animal Welfare and were approved by the local 
governmental authority. Animals were acclimatised a week prior use and general health 
status was monitored during the experiments. Female immunodeficient CB17 SCID mice 
(Charles River) 5- to 7-week-old received subcutaneously implanted tumour cell 
suspensions of Colo320 (5 Mio Cells in 100µl PBS + 1:1 (v/v) matrigel / animal) in the 
flank. Tumours were growing until a tumour volume range from 300-800mm³ (calculated 
L x W x W/2 from digital calliper measurements). Mice with appropriate tumour volume 
were stratified into control & treatment groups (n=5 / group). Administrations of vehicle or 
compound (formulated in 0.5% Methocel / 0.25% Tween20 / water) were orally given by 
gavage and tumours were collected at the respective time points after treatments for 
subsequent analysis. 
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Results  
MSC2504877 selectively inhibits tankyrase activity and growth of APC deficient cell 
lines. We identified precursors of MSC2504877 (Figure 1A) from a small molecule screen 
of roughly half a million compounds, where catalytic inhibition of recombinant TNKS1 was 
assessed in a cell free assay (Buchstaller et al., manuscript in preparation). Hit-to-lead 
and lead optimisation efforts focused on improving the metabolic stability and solubility of 
the original hit matter and resulted in the identification of MSC2504877 (Buchstaller et al., 
manuscript in preparation). 
  
Using in vitro biochemical assays, we found that MSC2504877 inhibited TNKS1 activity 
with an IC50 of 0.0007 mM and PARP1 activity with an IC50 of 0.54 mM, a 771-fold 
selectivity for TNKS1 (Figure 1B,C). Inhibition of tankyrase PARylation causes a 
decreased level of AXIN degradation, increased activity of the b-catenin destruction 
complex and a decreased level of b-catenin3. Western blotting of lysates derived from 
APC mutant COLO320DM colorectal tumour cells exposed to MSC2504877 indicated 
that MSC2504877 increased AXIN2 protein levels and decreased b-catenin levels (Figure 
1D), suppressed canonical Wnt signalling in SW480 cell line that stably expresses 
luciferase driven by a TCF-dependent promoter (Supplementary Figure 1) and 
suppressed mRNA levels of two key Wnt-driven transcripts, RUNX2 and AXIN2, as 
assessed by qRT-PCR (Supplementary Figure 2). MSC2504877 also caused tankyrase 
levels to rise (Figure 1D), consistent with MSC2504877 inhibiting autoPARylation and 
subsequent degradation of tankyrase3. These qualitative estimates of MSC2504877 
cellular activity were confirmed by the use of quantitative, antibody-based detection of 
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AXIN2 and TNKS (using a luminex-based detection system). This suggested that 
MSC2504877 increased both AXIN2 (Figure 1E) and TNKS (Figure 1F) protein levels. 
We also assessed whether MSC2504877 modulated tumoral Wnt signalling in vivo. To 
do this, we administered MSC2504877 (30 mg/kg) to mice bearing APC mutant 
COLO320DM tumour cell xenografts and recovered tumours for analysis 2-18 hours later. 
Using the luminex-based system, we found that MSC2504877 elicited an increase in both 
TNKS and AXIN2 levels in tumours, peaking at 6-10 hours after drug administration and 
falling 18 hours after MSC2504877 treatment (Figure 1G,H), a time course which was 
shifted when compared to the compound concentration time profile in mice (ttmax = 0.5 
h, Cmax = 7 µg/mL; Cl = 2.72 L/h/kg, Figure 1I), and thus in agreement with a turnover 
PK/PD model for a single dose administration of MSC2504877. Taken together, these 
observations suggested that MSC2504877 inhibited TNKS and Wnt signalling, both in 
vitro and in vivo. 
 
Previously described tankyrase inhibitors elicit synthetic lethality in tumour cells with APC 
tumour suppressor gene defects3. In the first instance, we assessed the cell inhibitory 
properties of MSC2504877 in an isogenic pair of APC wild type (APCWT) and APC 
defective (APC–/–) cells lines derived from the MCF10A non-tumour epithelial cell line. In 
this model, APC gene defects were generated by deletion of 17 bp within exon 16 of APC 
using gene targeting. In cell viability assays where APCWT and APC–/– isogenic cells were 
exposed to MSC2504877 for a five-day period, MSC2504877 significantly inhibited the 
survival of APC–/– cells, compared to APCWT cells (Figure 2A, ANOVA p=0.005). To 
assess whether this selectivity could also be achieved in colorectal tumour cell lines with 
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naturally occurring APC gene mutations, we assessed the effect of MSC2504877 in APC 
mutant (p.S811* homozygous) COLO320DM and APC wild type RKO colorectal tumour 
cell lines. In both five-day and two-week drug exposure survival assays, we found that 
MSC2504877 had a significantly greater effect in COLO320DM cells than in RKO cells 
(Figure 2B ANOVA p = 0.012 (five-day assay) and Figure 2C ANOVA p=0.001 (14-day 
assay)). We also noted that the cell inhibitory effect of MSC2504877 on COLO320DM 
was significantly more profound when an extended drug exposure of 14 days was used, 
compared to a five-day exposure (Figure 2B,C). 
 
Given the interest in using tankyrase inhibitors to target APC mutant colorectal cancers 
(CRC), we also assessed MSC2504877 sensitivity in a panel of CRC tumour cell lines. 
We carried out MSC2504877 sensitivity assays in 24 APC mutant models as well as five 
APC wild type models and found that the responses in the APC mutant models were 
varied, with some APC mutant models, such as COLO201, HCT15, HGC27 and LOVO, 
being profoundly resistant to single agent tankyrase inhibitor exposure (Figure 2D). 
Although the use of isogenic cell lines clearly identified APC synthetic lethality with 
MSC2504877 (Figure 2A), the varied responses in the panel of CRC tumour cell lines 
suggested that APC mutation alone might not be a fully penetrant biomarker of single 
agent tankyrase inhibitor response; we also did not find that the position of truncating 
mutations in APC correlated with MSC2504877, as has been suggested for other 
tankyrase inhibitors4. We assessed whether other cancer driver gene alterations found in 
CRC, such as those in TP53, SMAD4, PIK3CA, KRAS, ARID1A, SOX9 and FAM123B 
correlated with sensitivity to MSC2504877, but did not find, in this tumour cell line panel 
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at least, that gene mutations/copy number alterations in any of these strongly correlated 
with tankyrase inhibitor response.  
 
Integrated RNA interference and small molecule chemosensitisation screens 
identify CDK4/6 inhibition as a determinant of MSC2504877 sensitivity. To better 
understand what could drive sensitivity to MSC2504877, we carried out parallel RNA 
interference (RNAi) and small molecule/drug high-throughput chemosensitisation 
screens using MSC2504877 in APC mutant colorectal cancer tumour cell lines.  
 
For the small molecule/drug chemosensitisation screens, we plated COLO320DM cells 
(APC p.S811* homozygous and KRAS wild type) or SW480 cells (APC mutation 
p.N125K;p.F1197fs;p.S1278* heterozygous, KRAS mutation p.G12C heterozygous) in 
384 well plates containing MSC2504877 or the drug vehicle (DMSO), combined with a 
library of 80 small molecule inhibitors that are either already used in the treatment of 
cancer, or are in late stage development. To maximize the likelihood of identifying 
chemosensitization effects, each small molecule inhibitor in the library was present at 
eight different concentrations. Cells were then exposed to drugs for five continuous days, 
at which point cell viability was estimated by the use of Cell TitreGLo reagent (Figure 3A). 
Each tumour cell line was screened in triplicate, with median effects being used to 
estimate MSC2504877 sensitivity-causing effects. Replica screens showed a high level 
of reproducibility between independent replicas (r2 > 0.7) and a suitable dynamic range 
(Z’ >0.5).  
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To identify candidate chemosensitization effects, we calculated Drug Sensitisation (DE) 
robust Z scores describing the effect of each library drug on the response to 
MSC2504877; we defined those library drugs that elicited DE Z<-2 effects (approximately 
equivalent to p<0.05) with at least two different concentrations as being candidate 
sensitivity causing effects (Figure 3B,C). Amongst these sensitization effects, we noted 
the presence of previously reported effects, including tankyrase inhibitor sensitization 
caused by an EGFR inhibitor28, canertinib (MSC2504877 sensitisation effect in 
COLO320DM) and MSC2504877 sensitization caused by the multikinase inhibitor 
dasatinib19  (MSC2504877 sensitisation effect in both SW480 and COLO320DM) giving 
us some confidence in the results. Our intermediate aim was to identify sensitization 
effects that operated in a variety of APC mutant colorectal tumour cell lines; by 
intersecting the data from both COLO320DM and SW480 screens, we identified two 
drugs that caused MSC2504877 sensitivity in both: the mutlikinase inhibitor, dasatinib, 
identified in earlier work19, and the CDK4/6 kinase inhibitor palbociclib (PF-332991).  
 
Alongside these drug combination screens, we also carried out short interfering (si)RNA 
chemosensitisation screens using MSC2504877 (Figure 4A). COLO320DM cells were 
reverse transfected in 384 well plates using an siRNA library designed to target 1143 
genes, including a panel of protein kinases, genes included in the cancer gene census29 
and also, genes implicated in Wnt signaling, given the role of tankyrases in this molecular 
pathway. Twenty-four hours after siRNA transfection, cells were either exposed to 
MSC2504877 or the drug vehicle for a subsequent five days, at which point cell viability 
was estimated by the use of Cell TitreGlo reagent (Figure 4A). We performed three replica 
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screens, and combined the replicas in the final analysis. Replica screens showed a high 
level of reproducibility between independent replicas (r2 > 0.7) and a suitable dynamic 
range (Z’ >0.5). 
 
To identify candidate sensitivity and resistance-causing effects, we calculated Drug 
Sensitisation Z scores describing the effect of siRNA on the response to MSC2504877; 
we defined those siRNAs that elicited Z<-2 effects (approximately equivalent to p<0.05) 
as being candidate sensitivity-causing effects and, conversely defined Z>2 effects as 
resistance-causing. Candidate resistance-causing or sensitivity-causing siRNAs are 
illustrated in Figure 4C. We noted that one of the most profound resistance-causing 
effects was caused by siRNA designed to target AXIN2 (Figure 4C), an effect that 
confirmed previous observations made using a first-generation small molecule tankyrase 
inhibitor, XAV939, in APC mutant DLD1 CRC cells3. Using the Z score thresholds of Z<-
2 (sensitivity) and Z>2 (resistance), we selected siRNAs for further analysis in validation 
experiments. Of the 44 siRNAs selected for validation, we found in subsequent 
experiments that 13 caused sensitivity to MSC2504877 (FANCA, CDK4, FEN1, CDK7, 
RANBP17, ERCC3, PDGFA, PDGFRB, ADBRK1, SLC45A3, SETD2, CDK6 and 
PIK3CA) whilst 13 siRNAs caused MSC2504877 resistance (BTRC, RNF43, PMS2, 
TSC1, TSC2, CTNNBIP1, FAT1, BCOR, KREMEN1, PTEN, BCL7A, DCLRE1C, CUL1 
and AXIN2) (Figure 4D). In addition to AXIN2, we found that a number of other siRNA 
designed to target modifiers of Wnt signaling caused MSC2504877 resistance. These 
included siRNAs designed to target FAT1 or CTNNBIP1, proteins which normally bind β-
Catenin and impair its nuclear localization30, and CUL1, BTRC (β-TrCP) and AMER1 (also 
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known as FAM123B or WTX), proteins which normally mediate the proteosomal 
degradation of β-Catenin. These observations suggested that modulation of a series of 
additional Wnt pathway components, and specifically those that control the level of 
nuclear β-Catenin, could drive resistance to tankyrase inhibitors, similar to the 
observations made by de la Roche et al, who demonstrated that LEF1 and B9L, proteins 
that prevent Axin driven degradation of β-Catenin, reverse tankyrase inhibitor 
sensitivity31. We also noted that siRNA targeting PTEN, TSC1 or TSC2 also caused 
MSC2504877 resistance (Figure 4D), implicating the PI3-kinase/mTOR signaling 
cascade in controlling the response to MSC2504877. In terms of sensitivity causing 
effects, siRNA targeting PIK3CA, the gene encoding the catalytic domain of the major 
PI3-kinase enzyme, was also confirmed (Figure 4D). 
 
By cross referencing the results from the small molecule chemosensitisation screens and 
the siRNA screen, we noted that siRNAs targeting CDK4 or CDK6 also caused sensitivity 
to MSC2504877 (Figure 4C,D), corroborating the results seen with the CDK4/6 inhibitor 
palbociclib in the small molecule sensitisation screens (Figure 3). We investigated this 
further, initially by assessing whether sensitivity to MSC2504877 caused by palbociclib 
was specific to the COLO320DM model or was also found in additional CRC tumour cell 
line models. 
 
Tankyrase inhibitor sensitisation by CDK4/6 inhibition is not specific to palbociclib 
or MSC2504877. We confirmed that palbociclib caused MSC2504877 sensitivity in 
COLO320DM cells (Figure 5A-D) and found that a chemically distinct CDK4/6 inhibitor, 
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abemaciclib (LY2835219, Eli Lily), also elicited a synergstic effect with MSC2504877 
(Figure 5E). Furthermore, we found that a toolbox tankyrase inhibitor, NVP-656, also had 
a synergistic interaction with palbociclib (Figure 5F). These observations suggested that 
the CDK4/6 inhibitor vs. tankyrase inhibitor synergistic effects were not specific to 
MSC2504877 or palbociclib. In addition, we assessed whether the MSC2504877 
sensitisation effect caused by palbociclib was specific to COLO320DM cells. We found 
that palbociclib/ MSC2504877 synergy existed in SW480 (APC p.Q1338* homozygous, 
KRAS p.G12V homozygous and amplified), SW620 (APC Q1338* homozygous, KRAS 
p.G12V homozygous and amplified) and SW403 (APC mutation 
p.N125K;p.F1197fs;p.S1278* heterozygous, KRAS mutation p.G12C heterozygous) 
CRC tumour cell lines (Figure 5G).  
 
Simultaneous exposure to MSC2504877 and palbociclib enhances G1/S cell cycle 
arrest and a senescence phenotype. CDK4 and CDK6 are cyclin dependent kinases 
that with their Cyclin D-family partners, work within a network of tumour suppressor 
proteins and oncogenes that control the progression of the cell cycle. For example, the 
tumour suppressor protein, CDKN2A (p16INK4a) inhibits CDK4 and CDK6, events that 
reduce their ability to phosphorylate and inactivate the Rb (RB1) tumour suppressor 
protein. This function of CDKN2A in the CDKN2A, CDK4/6, Rb signaling cascade alters 
the activity of a series of Rb-controlled E2F family transcription factors, which in turn 
suppress G1/S cell cycle progression. This suppression of G1/S cell cycle progression 
also often leads to cellular senescence. In the absence of CDKN2A, a common driver 
event in human cancers, the control of the G1/S cell cycle checkpoint is impaired. Small 
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molecule CDK4/6 inhibitors, such as palbociclib, elicit their anti-tumour effects in part by 
reinstating the G1/S checkpoint in tumour cells that still have the ability to express Rb; this 
often leads to cellular senescence32. Palbociclib has been approved for use as part of 
drug combination regimens in estrogen receptor positive advanced breast cancer33,34. In 
colorectal cancers, the CDKN2A, CDK4/6, Rb signaling cascade might also control 
tumourigenesis driven by loss of wild type APC function. For example, in a mouse model 
of adenoma formation, Apc dysfunction causes an increase in Cyclin D2 and CDK4 
expression and a corresponding increase in hyperphosphorylated Rb35. Furthermore, 
Cyclin D2 causes a reduction in enterocyte proliferation and crypt size in Apc-deficient 
intestinal epithelia, and CDK4/6 inhibition limits the proliferation of adenomatous cells, but 
not normal cells, in Apc(Min/+) mice35. 
 
Based on these observations, we assessed whether the combination of palbociclib and 
MSC2504877 caused a change in cell cycle progression. FACS profiling of COLO320DM 
cells demonstrated that MSC2504877 exposure alone had negligible effects on the cell 
cycle, whilst, palbociclib caused a modest, concentration dependent, increase in the G1 
fraction of cells (G1 fraction increased from 56 % to 66 % in response to 0.3 µM palbociclib 
after 24 hours of treatment and 54 % to 60% after 144 hours of treatment) (Figure 6A). 
However, in contrast to the single agent effects, the combination of MSC2504877 and 
palbociclib caused a supra-additive increase in the G1 fraction (G1 fraction increased from 
56 % to 77 % at 24 hours and 54 % to 70% at 144 hours, Figure 6A). We also noted that 
whilst single agent use of either palbociclib or MSC2504877 alone had negligible effects 
on the proportion of COLO320DM cells exhibiting a senescent phenotype (as estimated 
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by b-galactosidase staining), exposure to both agents caused a clear increase in b-
galactosidase positive cells (Figure 6B). Taken together, this suggested that the 
synergistic effect of palbociclib when used with MSC2504877, could be explained by a 
supra-additive effect on the G1/S cell cycle checkpoint and the induction of cellular 
senescence, phenotypes reminiscent of a re-instated Rb-mediated signaling cascade. 
 
To investigate the molecular features of this effect, we assessed the expression and 
phosphorylation status of a series of proteins involved in the CDKN2A, CDK4/6, Rb 
signaling cascade when cells were exposed to a palbociclib/MSC2504877 combination 
(Figure 6C-E). We found that whilst exposure to palbociclib caused an increase in Cyclin 
D2 and Cyclin E2 levels, presumably a mechanism by which the cells override the G1 cell 
cycle blockade initiated by CDK4/6 inhibition, the addition of MSC2504877 suppressed 
these Cyclin D2/E2 responses (Figure 6C,D). We also noted a time dependent effect on 
the levels of phosphorylated Rb (S807-811); as expected, palbociclib exposure elicited a 
decrease in level of phosphorylation after 24 hrs of exposure (Figure 6E,F). However, 
after 72 hrs, levels of phosphorylated Rb in cells exposed to palbociclib were restored to 
those in cells exposed to the drug vehicle, DMSO (Figure 6E,F). In contrast, the addition 
of MSC2504877 to palbociclib maintained the suppression of phosphorylated Rb levels 
over the 72 hour time course (Figure 6E,F). These observations, taken together with the 
FACS profiling data, were consistent with the hypothesis that MSC2504877, when 
combined with palbociclib, reinforces G1 cell cycle arrest and ultimately causes cells to 
senesce. The CyclinD2-coding gene, CCND2, is a transcriptional target of canonical Wnt 
signalling. Using RT-PCR, we found that palbociclib exposure caused an upregulation of 
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CCND2 mRNA levels (Figure 6G), commensurate with the increase in Cyclin D2 protein 
levels seen earlier (Figure 6C,D); this increase in CCND2 mRNA levels was reduced to 
basal levels when cells were also exposed to MSC2504877 (Figure 6G), providing a 
mechanistic explanation for the combined tumour cell inhibitory effects of palbociclib and 
MSC2504877.  
 
Palbociclib plus MSC2504877 combination suppresses hyperproliferation in Apc 
defective cells in vivo. To assess whether these effects operated in an in vivo setting, 
we assessed the impact of a MSC2504877 + palbociclib combination in genetically 
engineered mice carrying Villin-CreERT2 and homozygous for the Apcfl allele; tamoxifen-
induced, Cre-mediated recombination in this mouse model drives homozygous deletion 
of Apc in the entire intestinal epithelium, aberrant activation of the Wnt pathway and as 
consequence, dramatic intestinal crypt expansion36 (Figure 7A). In the first instance, we 
dosed Villin-CreERT2; Apcfl/fl mice with either single agent MSC2504877 (50mg/kg), single 
agent palbociclib (150 mg/kg), or a MSC2504877 (50 mg/kg) + palbociclib (150 mg/kg) 
combination. Whilst neither single agent drug administration suppressed intestinal crypt 
expansion caused by Apc deletion, the combination of MSC2504877 with palbociclib had 
a dramatic suppressive effect, as seen both by the gross histology of tissue sections 
isolated from mice (Figure 7B), and also a profound reduction in bromodeoxyuridine 
(BrdU) incorporation in intestinal crypts (Figure 7C). These effects were apparent using 
a 50 mg/kg MSC2504877 + 150 mg/kg palbociclib combination (“high dose combination”, 
(HD)), as well at lower concentrations of MSC2504877 + palbociclib (20 mg/kg + 37.5 
mg/kg, respectively, “low dose combination” (LD) Figure 7B,C). Combined exposure to 
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MSC2504877 + palbociclib also suppressed the expression of the archetypal Wnt target 
gene and stem cell marker Lgr5 (Figure 7D,E) and combination drug treatment caused a 
profound increase in nuclear p21 (Figure 7F), consistent with an effect on mechanisms 
of G1/S cell cycle control.  
 
In many human tumours, including colorectal cancers, loss of function APC mutations co-
occur with mutation in KRAS. We also exploited genetically engineered mice to assess 
whether the presence of a Kras mutation might modulate the effects of a tankyrase 
inhibitor/CDK4/6 inhibitor combination. To do this, we assessed the crypt hyper-
proliferative phenotype in Villin-CreERT2; Apcfl/fl; KRasLSL-G12D/+ mice37 (Figure 7G). By 
examination of the gross histology of tissue sections (Figure 7H), and BrdU incorporation 
(Figure 7I), we found that the presence of the KRasG12D mutation reversed the inhibitory 
effects of the MSC2504877 + palbociclib combination. 
 
 
Discussion  
Here we describe the characterisation of a novel tankyrase inhibitor, MSC2504877. Along 
with biochemical and cellular assays carried out to assess its potency and selectivity, we 
demonstrate that combination with CDK4/6 inhibitors has a supra-additive effect on 
tumour cells. Dissection of this effect suggests that this combinatorial effect might be 
mediated by the ability of MSC2504877 to suppress the upregulation of Cyclin D2 levels. 
This appears to be a distinct mechanism to those proposed for other tankyrase inhibitor 
combinations. For example, the supra-additive effect of a tankyrase inhibitor combined 
with a MEK inhibitor is proposed to be mediated via the ability of tankyrase inhibition to 
suppress a FGFR2-mediated feedback loop that is otherwise activated by MEK 
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inhibition19. Tankyrase inhibitors have been also shown to sensitise lung cancer cells to 
EGFR inhibition through a mechanism that involves stabilisation of angiomotins and 
inhibition of YAP signalling38. It thus seems reasonable to propose that there might be 
multiple, distinct, routes by which tankyrase inhibition alter the homeostatic response to 
other drugs. 
 
One challenge associated with the development of tankyrase inhibitors as a treatment for 
cancer has been the intestinal toxicity observed in pre-clinical animal models. Wnt/β 
catenin signalling maintains homeostasis in the intestinal epithelium; inhibition of Wnt/β 
catenin signalling results in terminal differentiation of stem cells and loss of crypt structure 
39,40. It seems possible that the suppression of Wnt/β catenin signalling via tankyrase 
inhibition in intestinal stem cells is an explanation, at least in part, for the intestinal toxicity 
seen with tankyrase inhibitors. This in turn, might challenge the concept of therapeutically 
targeting canonical Wnt signalling as a therapeutic approach. However, preliminary data 
from a phase 1 clinical trial of WNT974, an inhibitor of porcupine (a membrane-bound O-
acyltransferase enzyme required for Wnt ligand secretion), reports a manageable safety 
profile as well as suppression of a key Wnt/β catenin target gene, AXIN241. Whether 
CDK4,6 inhibitors might also have combinatorial effects with Porcupine inhibitors or other 
drug targets in Wnt/β catenin signalling cascade remains to be seen. 
 
In summary, MSC2504877 is a novel, drug-like, tankyrase inhibitor that inhibits APC 
mutant colorectal tumour cells. Parallel siRNA and drug sensitivity screens show that the 
clinical CDK4/6 inhibitor palbociclib, causes enhanced sensitivity to MSC2504877. This 
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tankyrase inhibitor - CDK4/6 inhibitor combinatorial effect is not limited to palbociclib and 
MSC2504877 and is elicited with other CDK4/6 inhibitors and other tankyrase inhibitors, 
namely NVP-656. Nevertheless, it is possible that these effects are private to the 
tankyrase inhibitors/CDK4/6 inhibitors tested. The addition of MSC2504877 to palbociclib 
enhances G1 cell cycle arrest and cellular senescence. MSC2504877 exposure 
suppresses the upregulation of Cyclin D2 and Cyclin E2 caused by palbociclib and 
enhances the suppression of phopho-Rb. Combinatorial effects of MSC2504877 and 
palbociclib are also seen in suppressing the cellular hyperproliferative phenotype seen in 
Apc defective intestinal stem cells in vivo. 
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Figure legends  
Figure 1. MSC2504877 is a novel, drug-like, small molecule tankyrase inhibitor. A. 
Structure of MSC2504877. B. Dose-response curve illustrating the inhibition of 
recombinant tankyrase (TNKS) or PARP1 with MSC2504877A. Tankyrase activity was 
assayed using the PARP domain of recombinant human Tankyrase (TNKS) or PARP1 in 
an ELISA assay. Mean dose response data from three independent experiments is 
shown. Error bars represent standard error of the mean (SEM). C. Table illustrating IC50 
concentrations obtained for MSC2504877A and two toolbox tankyrase inhibitors. TNKS, 
TNKS2 and PARP1 activity was determined as in (B). D. Western blot illustrating 
tankyrase stabilisation, suppression of b-catenin and stabilisation of Axin 2 protein levels 
in COLO320DM (APC mutant) colorectal tumour cells exposed to MSC2504877 for 24 
hours as shown. α-Tubulin was used as loading control. E, F. Luminex antibody-based 
detection of AXIN2 and TNKS in COLO320DM cells exposed MSC2504877 in vitro. Dose 
response data from three independent experiments are shown; error bars represent 
standard deviations. G, H. Luminex detection of AXIN2 and TNKS in COLO320DM 
xenografts. CB17 SCID mice received 30 mg/kg MSC2504877 via an oral route. At the 
time points indicated, mice were sacrificed and xenografts recovered. Each data point 
indicates data from one animal. I. Plasma concentration time profile of MSC2504877 after 
one single oral dose of 30 mg/kg. 
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Figure 2. MSC2504877 elicits APC synthetic lethality. A, B, C. MSC2504877 
selectively targets APC defective cells. Dose response survival curves are shown for (A) 
MCF10A APC +/+ and APC –/– isogenic cells, or (B) COLO320DM (APC defective) and 
RKO (APC wild type) colorectal tumour cells continuously exposed to MSC2504877 for a 
total of five days and (C) COLO320DM and RKO cells continuously exposed to 
MSC2504877 for a total of 14 days. Experiments were conducted in in media containing 
0.5 % (v/v) FCS. Dose response data from three independent experiments are shown; 
error bars represent SEM. p values were calculated using ANOVA. D. MSC2504877 
sensitivity in 23 colorectal tumour cell lines. Tumour cell lines were profiled for sensitivity 
to five-day exposure to MSC2504877, as in (B), in media containing 0.5 % (v/v) FCS. Bar 
chart illustrating EC50 values is shown.  
 
Figure 3. Small molecule chemosensitisation screens identify palbociclib as a 
candidate MSC2504877 sensitising agent. A. Schematic of MSC2504877 
chemosensitisation screens in colorectal tumour cells. COLO320DM and SW80 cells 
were exposed to 80 library drugs (at eight different concentrations, arrayed in two 384-
well plates) for five continuous days, in the presence or absence of MSC2504877, at 
which point cell viability was estimated. Cell viability data was used to calculate drug 
sensitisation Z scores. Library drugs that elicited Z scores of <-2 at more than one 
different concentration were selected as candidate MSC2504877 chemosensitisation 
effects, and shown in (B) and (C). B,C. Bar charts illustrating candidate MSC2504877 
chemosensitisation effects in SW480 cells (B) and COLO320DM cells (C). Dasatinib and 
palbociclib chemosensitisation effects in both cell lines are highlighted.  
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Figure 4. A RNA interference (RNAi) sensitisation screen identifies candidate 
MSC2504877 sensitivity- and resistance-causing effects. A. Schematic of RNAi 
screen in colorectal tumour cells. COLO320DM cells were transfected with 1599 different 
siRNA SMARTPools (arrayed in five different 384 well-plates) and then cultured for five 
continuous days in the presence or absence of MSC2504877. At this point, cell viability 
was estimated. Cell viability data was used to calculate drug sensitisation Z scores. 
siRNAs that elicited Z scores of <-2 or >2 were selected as candidate MSC2504877 
sensitisation/resistance-causing effects, shown in (C). B. Scatter plot illustrating the effect 
of control siRNAs on cell viability in COLO320DM cells. siRNA designed to target Polo-
like kinase 1 (PLK1) caused profound cell inhibition, when compared to three different 
non-targeting siRNAs (Allstar, siCON1 and siCON2). C. Bar chart illustrating drug 
sensitisation Z scores of “hits” identified in the screen. D. Bar chart illustrating 
MSC2504877 responses in post-screen validation experiments. COLO320DM cells were 
transfected with SMARTpool siRNA and then exposed to MSC2504877 for five days at 
which point cell viability was estimated. Effects of CDK4 and CDK6 siRNA SMARTpools 
are highlighted in red, both of which significantly enhanced MSC2504877 sensitivity, 
compared to control, non-targeting siRNAs (Allstar and siCON1). Dark grey columns 
indicate additional MSC2504877 sensitivity-causing siRNAs, whilst light grey bars 
indicate MSC2504877 resistance-causing effects. Validation was carried out in a 384 
well-plate five day assay. Ratio of survival fraction in the MSC2504877A exposed cells 
compared to DMSO exposed cells is plotted. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, ****  p 
≤ 0.0001, Student’s t test. Error bars represent SEM from triplicate experiments. 
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Figure 5. CDK4/6 inhibitors sensitise tumour cells to tankyrase inhibitors. A, B, C. 
Dose response cell survival curve for COLO32DM cells exposed to (A) MSC2504877, (B) 
palbociclib, or (C) the combination of MSC2504877 plus palbociclib, for five days. Mean 
effect from three independent experiments is shown; error bars represent SEM. D. 
Synergy volume plot indicating supra-additive effect of MSC2504877 plus palbociclib in 
COLO320DM cells. Synergy volumes >50 are regarded as strong synergistic effects. E, 
F. Dose response cell survival curve for COLO32DM cells exposed to (E) MSC2504877 
plus abemaciclib, or (B) NVP656 plus palbociclib, for five days. Mean effect from three 
independent experiments is shown; error bars represent SEM. G. Bar chart of synergy 
volumes from MSC2504877 plus palbociclib dose response experiments in colorectal 
tumour cells. Colorectal tumour cells were exposed to MSC2504877 plus palbociclib in 
triplicate experiments as in A,B,C,D. Synergy volumes were calculated using 
MacSynergyII. 
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Figure 6. MSC2504877 + palbociclib combination elicits G1 cell cycle effects. A. Bar 
chart illustrating cell cycle fractions in COLO320DM cells exposed to MSC2504877 plus 
palbociclib. Numbers in boxes reflect % of total cell number. B. Microscopy images 
illustrating b-galactosidase staining in COLO320DM cells exposed to MSC2504877 plus 
palbociclib. Blue staining indicates b-galactosidase positive cells. Scale bar represents 
10 microns. C. Western blot image illustrating Cyclin D2, Cyclin E2 and CDK4 protein 
levels in COLO320DM cells exposed to MSC2504877. Palbociclib causes an increase in 
Cyclin D2 and Cyclin E2 protein levels, which is suppressed by MSC2504877. D. Bar 
chart illustrating band densiometry measurements from (C). E. Western blot image 
illustrating phospho-Rb suppression in COLO320DM cells exposed to MSC2504877 and 
palbociclib. Palbociclib alone causes a transient suppression in phospho-Rb levels (at 24 
and 48 hours). The addition of MSC2504877 temporally extends phospho-Rb 
suppression. F. Bar chart illustrating band densiometry measurements from (E). G. Bar 
chart illustrating normalised RT-PCR measurements from COLO320DM cells exposed to 
MSC2504877 plus palbociclib for 24 hours. Data shown is from triplicate experiments. 
Error bars represent SEM.  
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Figure 7. Palbociclib plus MSC2504877 combination suppresses the intestinal 
hyperproliferation phenotype in Villin-CreERT2; Apcfl/fl mice. A. Schematic of Villin-
CreERT2; Apcfl/fl model system. B. Images of hematoxylin and eosin stained intestinal 
tissue from Villin-CreERT2; Apcfl/fl mice. Animals received vehicle, MSC2504877, 
palbociclib or a combination of MSC2504877 plus palbociclib for 3 continuous days.  
Combination HD = high dose combination, 50 mg/kg MSC2504877 + 150 mg/kg 
palbociclib. Combination LD = low dose combination, 20 mg/kg MSC2504877 + 37.5 
mg/kg palbociclib. C. Images of intestinal tissue from Villin-CreERT2; Apcfl/fl mice 
immunohistochemically stained for BrdU incorporation. Mice were treated as in (B). D. 
Images of intestinal tissue from Villin-CreERT2; Apcfl/fl mice immunohistochemically stained 
with an RNAscope probe directed against Lgr5 mRNA. Mice were treated as in (B). E. 
Images of intestinal tissue whole mounts from Villin-CreERT2; Apcfl/fl mice stained with an 
RNAscope probe directed against Lgr5 mRNA . Mice were treated as in (B). Arrows in 
control sample image indicates presence of Lgr5 expression; arrows in combination 
(TNKSi + Palbociclib) treated mice image shows absence of Lgr5 expression. F. Images 
of intestinal tissue from Villin-CreERT2; Apcfl/fl mice immunohistochemically stained for the 
presence of p21. Mice were treated as in (B). G. Schematic of Villin-CreERT2; Apcfl/fl; 
KRasLSL-G12D/+ model system. H. Images of hematoxylin and eosin stained intestinal tissue 
from Villin-CreERT2; Apcfl/fl; KRasLSL-G12D/+ mice. Animals received vehicle, MSC2504877, 
palbociclib or a combination of MSC2504877 plus palbociclib.  Combination HD = high 
dose combination, 50 mg/kg MSC2504877 + 150 mg/kg palbociclib. Combination LD = 
low dose combination, 20 mg/kg MSC2504877 + 37.5 mg/kg palbociclib. I. Images of 
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intestinal tissue from Villin-CreERT2; Apcfl/fl; KRasLSL-G12D/+ mice immunohistochemically 
stained for BrdU incorporation. Mice were treated as in (H).  
 
 
 
A. B. 
C. D. 
E. 
MSC2504877
Fo
ld
 c
ha
ng
e
co
m
pa
re
d 
to
 D
M
SO
2 hr incubation
6 hr incubation, EC50 1.04 x10-8 M
24 hr incubation, EC50 1.89 x10-8 M
2 hr incubation
6 hr incubation
24 hr incubation, EC50 1.47 x10-8 M
[MSC2504877] log10 (M)
TNKSAXIN2
Fo
ld
 c
ha
ng
e
co
m
pa
re
d 
to
 v
eh
ic
le
Vehicle 30 mg/kg MSC2504877
one dose
Vehicle 30 mg/kg MSC2504877
one dose
DMSO
MSC2504877 (µM) olaparib (µM)
10 3 1 10 3
TNKS
b-catenin
AXIN2
a-Tubulin
TNKSAXIN2
[MSC2504877] log10 (M)
G. 
Time (h)
C
on
ce
nt
ra
tio
n 
(n
g/
m
L)
Mean plasma concentration +/- SD
F. 
H. I. 
Fo
ld
 c
ha
ng
e
co
m
pa
re
d 
to
 D
M
SO
10-11 10-10 10-9 10-8 10-7 10-6 10-5
-100
-50
0
[MSC2504877A] (M)
%
 a
ct
iv
ity
 
% activity TNKS
% activity PARP1
TNKS 
IC50 
[µM]
TNKS2 
IC50 
[µM]
PARP1 
IC50 
[µM]
XAV939 0.01 0.005 0.155
IWR-1 0.18 0.06 -
MSC
2504877
A
0.0007 0.0008 0.54
A. 
-10 -8 -6 -4
0
25
50
75
100
125
MSC2504877A (Log10M)
%
 c
el
l s
u
rv
iv
al
MCF10A APC parental
MCF10A APC null
p = 0.005
B. 
[MSC2504877] log10 (M)
Su
rv
iv
in
g 
Fr
ac
tio
n 
(%
) 
MCF10A APC –/–
MCF10A APC +/+
*ANOVA p = 0.005 **ANOVA p < 0.001
Cell survival after
5 days inhibitor exposure
[MSC2504877] log10 (M)
C. 
Cell survival after
5 days inhibitor exposure
[MSC2504877] log10 (M)
* **
SK
CO
1 
LS
51
3 
SW
94
8 
SW
48
0 
SW
40
3 
SW
14
63
 
CO
LO
67
8 
SW
83
7 
CO
LO
32
0D
M
NC
IH
74
7 
OU
MS
-23
 
SW
62
0 
SW
14
17
 
LS
41
1N
 
DL
D1
 
MD
ST
8 
RK
O
HT
29
HC
C2
29
8
LO
VO
 
HC
T1
5 
CO
LO
20
1
HG
C2
7 
-3
-2
-1
0
1
2
Cell lines
Lo
g 
[E
C
50
]
    APC + KRAS mutant
  KRAS mutant
APC mutant
Wildtype APC + KRAS
Su
rv
iv
in
g 
Fr
ac
tio
n 
(%
) 
Su
rv
iv
in
g 
Fr
ac
tio
n 
(%
) 
SK
CO
1 
LS
51
3 
SW
94
8 
SW
48
0 
SW
40
3 
SW
14
63
 
CO
LO
67
8 
SW
83
7 
CO
LO
32
0D
M
NC
IH
74
7 
OU
MS
-23
 
SW
62
0 
SW
14
17
 
LS
41
1N
 
DL
D1
 
MD
ST
8 
RK
O
HT
29
HC
C2
29
8
LO
VO
 
HC
T1
5 
CO
LO
20
1
HG
C2
7 
-3
-2
-1
0
1
2
Cell lines
Lo
g 
[E
C
50
]
    APC + KRAS mutant
  KRAS mutant
APC mutant
Wildtype APC + KRAS
D. 
Cell survival after
14 days inhibitor exposure
***ANOVA p < 0.001
***
• 384 well plate drug sensitivity screens
• 80 drugs
• 8 concentrations
• Five day drug exposure
• Three replica screens combined in final analysis
COLO320DM or SW480 + MSC2504877 - MSC2504877
x 3 x 3 
x 3 x 3 
Plate 1
Plate 2
A. 
-3.5
-3
-2.5
-2
-1.5
-1
-0.5
0
ca
ne
rti
ni
b 
 - 
 1
 n
M
ca
ne
rti
ni
b 
 - 
 1
0 
nM
da
sa
tin
ib
  -
  5
 n
M
da
sa
tin
ib
  -
  1
0 
nM
da
sa
tin
ib
  -
  1
00
 n
M
G
SK
19
04
52
9A
  -
  5
0 
nM
G
SK
19
04
52
9A
  -
  1
00
 n
M
pa
lb
oc
icl
ib
  -
  1
0 
nM
pa
lb
oc
icl
ib
  -
  5
00
 n
M
pa
lb
oc
icl
ib
  -
  1
00
0 
nM
sa
lin
om
yc
in
  -
  0
.5
 n
M
sa
lin
om
yc
in
  -
  5
0 
nM
-12
-10
-8
-6
-4
-2
0
AB
T-
73
7 
 - 
 5
00
 n
M
AB
T-
73
7 
 - 
 1
00
0 
nM
bl
eo
m
yc
in
su
lfa
te
  -
  1
00
 n
M
bl
eo
m
yc
in
su
lfa
te
  -
  5
00
 n
M
ce
le
co
xi
b 
 - 
 5
0 
nM
ce
le
co
xi
b 
 - 
 1
00
 n
M
ce
le
co
xi
b 
 - 
 1
00
0 
nM
da
sa
tin
ib
  -
  0
.5
 n
M
da
sa
tin
ib
  -
  5
 n
M
da
sa
tin
ib
  -
  1
00
 n
M
da
sa
tin
ib
  -
  5
00
 n
M
da
sa
tin
ib
  -
  1
00
0 
nM
do
xo
ru
bi
cin
.H
C
l  
-  
50
 n
M
do
xo
ru
bi
cin
.H
C
l  
-  
10
00
 n
M
im
at
in
ib
m
es
yl
at
e 
 - 
 5
0 
nM
im
at
in
ib
m
es
yl
at
e 
 - 
 1
00
 n
M
im
at
in
ib
m
es
yl
at
e 
 - 
 1
00
0 
nM
O
SI
-9
06
  -
  5
00
 n
M
O
SI
-9
06
  -
  1
00
0 
nM
pa
lb
oc
icl
ib
  -
  5
 n
M
pa
lb
oc
icl
ib
  -
  5
0 
nM
PF
-0
23
41
06
6 
 - 
 5
00
 n
M
PF
-0
23
41
06
6 
 - 
 1
00
0 
nM
PL
X-
47
20
  -
  5
0 
nM
PL
X-
47
20
  -
  1
00
 n
M
sa
pa
cit
ab
in
e 
 - 
 5
 n
M
sa
pa
cit
ab
in
e 
 - 
 5
00
 n
M
sa
pa
cit
ab
in
e 
 - 
 1
00
0 
nM
B. 
C. 
D
ru
g 
se
ns
iti
sa
tio
n 
Z 
sc
or
e
SW
40
3
Criteria for hit selection (B and C)
Z <-2 drug sensitisation effects 
caused by >1 concentration of drug
Dasatinib Palbociclib
Dasatinib Palbociclib
D
ru
g 
se
ns
iti
sa
tio
n 
Z 
sc
or
e
C
O
LO
32
0D
M
COLO320DM
• 384 well plate siRNA sensitivity screens
• 1599 genes
• Five day drug exposure
• Three replica screens combined in final 
analysis
x 3 x 3 
x 3 x 3 
x 3 x 3 
x 3 x 3 
x 3 x 3 
Plate 1
Plate 2
Plate 3
Plate 4
Plate 5
AllStar siCON1 siCON2
siPLK1
C
O
LO
32
0D
M
 Z
 S
co
re
 in
 D
M
SO
 
ex
po
se
d 
ce
lls
-35
-30
-25
-20
-15
-10
-5
0
5
A. 
B. 
FA
NC
A
CD
K7
FA
NC
A
AT
M
AD
RB
K1
ER
CC
1
FE
N1
ER
CC
3
CD
K7
EP
30
0
HI
ST
1H
4I
RB
M1
5
AT
M
CD
K4
CD
K6
ER
CC
3
BR
D3
PD
GF
RA
RA
NB
P1
7
SR
GA
P3
RO
BO
2
PD
GF
RB
PI
K3
CASR
C
PO
RC
N
AX
IN
1
TS
C1
CD
H1
PT
EN
BC
OR
AM
ER
1
PM
S2
AX
IN
1
DC
LR
E1
C
AX
IN
2
FA
T1
TS
C2
BC
L7
A
BT
RC
AM
ER
1
KR
EM
EN
1
CT
NN
BI
P1
CU
L1
TS
C2
-10
-5
0
5
10
siRNA
D
ru
g 
ef
fe
ct
  Z
-s
co
re
C.
D
ru
g 
se
ns
iti
sa
tio
n 
Z 
sc
or
e
C
O
LO
32
0D
M
DM
SO
 M
OC
K
87
7 
M
OC
K
Al
ls
ta
r
si
Co
n 
1
TN
KS
1
TN
KS
2
TN
KS
1/
2
AX
IN
2
FA
NC
A
CD
K4
FE
N1
CD
K7
RA
NB
P1
7
PD
GF
RA
ER
CC
3
PD
GF
RB
AD
RB
K1
SL
C4
5A
3
SE
TD
2
CD
K6
PI
K3
CA
HI
ST
1H
4I
ER
CC
1
BR
D3
AT
M
RO
BO
2
EP
30
0
SR
GA
P3
RB
M
15
PO
RC
N
PO
T1
SR
C
AM
ER
1
BT
RC
CD
H1
RN
F4
3
PM
S2
TS
C1
TS
C2
CT
NN
BI
P1
FA
T1
BC
O
R
KR
EM
EN
1
PT
EN
BC
L7
A
DC
LR
E1
C
CU
L1
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Fo
ld
 ch
an
ge
 in
 S
F
Controls
**
**
** ** ** * ** ** **
** ** *
* *
* *
* *
* * ** * * ** **
***
***
* P ≤ 0.05
** P ≤ 0.01
*** P ≤ 0.001
**** P ≤ 0.0001 
Su
rv
iv
in
g 
Fr
ac
tio
n
**
Vs. Allstar + MSC2504877D.
+ MSC2504877 - MSC2504877
AXIN2
MSC2504877 sensitivity-causing
MSC2504877 resistance-causing
-7 -60
0
50
100
MSC2504877A (Log10 M)
%
 c
el
l s
ur
vi
va
l
-8 -7 -6 -50
0
50
100
PD 0332991(Log10M)
%
 c
el
l s
ur
vi
va
l
-7 -60
0
50
100
MSC2504877A (Log10 M)
%
 c
el
l s
ur
vi
va
l
10
3.33
1.11
0.37
0.123
0.041
0.0137
DMSO
PD 0332991 (uM)
Su
rv
iv
in
g 
Fr
ac
tio
n 
(%
)
[MSC2504877] log10 (M) [Palbociclib] log10 (M)
Su
rv
iv
in
g 
Fr
ac
tio
n 
(%
)
Su
rv
iv
in
g 
Fr
ac
tio
n 
(%
)
[MSC2504877] log10 (M)
COLO320DM MSC2504877 + palbociclib
[Palbociclib] (µM)
Synergy volume = 223.48
[M
SC
25
04
87
7] 
(µ
M
)
Sy
ne
rg
y 
sc
or
e
Synergy score
A. B. 
C. D. 
[Palbociclib] (µM)
-7 -60
0
50
100
MSC2504877A Log10M
%
 c
el
l s
ur
vi
va
l
10
3.33
1.11
0.37
0.123
0.041
0.0137
DMSO
LY2835219 (uM)[Abemaciclib] (µM)
Su
rv
iv
in
g 
Fr
ac
tio
n 
(%
)
[MSC2504877] log10 (M)
-8 -7 -6 -50
0
50
100
NVP656 Log10M
%
 c
el
l s
ur
vi
va
l
10
3.33
1.11
0.37
0.123
0.041
0.0137
DMSO
PD 0332991 (uM)
Su
rv
iv
in
g 
Fr
ac
tio
n 
(%
)
[NVP656] log10 (M)
G. 
E. 
[Palbociclib] (µM)
SW
48
* S
KC
O1
 
MC
F7
* H
T2
9
* S
W8
37
* M
DS
T8
* N
CI
H7
47
* H
T5
5
SW
48
 KR
AS
 G
12
V
* D
LD
1
* H
CT
15
HC
T1
16
* S
W4
03
* C
OL
O3
20
DM
* S
W6
20
* S
W4
80
0
50
100
150
200
250
300
Cell lines
M
SC
25
04
87
7A
+P
al
bo
ci
cl
ib
 s
yn
er
gy
 s
co
re
*           APC mutant
KRAS mutant
Sy
ne
rg
y 
vo
lu
m
e
*APC mutant
KRAS mutant
F. 
A. 
B. 
Cyclin E2
Cyclin D2
CDK4
b - tubulin
–
–
+
–
–
+
+
+
MSC2504877 10 µM
Palbociclib 0.5 µM
48 hours drug exposure 72 hours drug exposure
–
–
+
–
–
+
+
+
C. D. 
24 hrs drug exposure 144 hrs drug exposure
56.1 58.5
66.4
59
63.4
76.9
21.6
22
15.8
18.8
15.8
10.4
18.6 16.4
15.1
18.5 17.5
10.1
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
53.5 55.4
59.7
52.3 55.1
69.6
22.2
22.4
17.7
17.9
18.6
14.5
19.1 17.6 19.2
21.7
19.5
9.9
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Fr
ac
tio
n 
of
 to
ta
l c
el
l p
op
ul
at
io
n 
(%
)
’877 (µM)
Palbo (µM)
–
–
–
0.03
–
0.30
1.00
–
1.00
0.03
1.00
0.30
G1 S G2 Sub G1 4N
–
–
–
0.03
–
0.30
1.00
–
1.00
0.03
1.00
0.30
0
0.5
1
1.5
0
0.5
1
1.5
Cyclin E2 – 48 hours
0
0.5
1
1.5
2
0
0.5
1
1.5
2
Cyclin D2 – 48 hours
0
0.5
1
1.5
2
CDK4 – 48 hours
0
0.5
1
1.5
2
R
el
at
iv
e 
am
ou
nt
R
el
at
iv
e 
am
ou
nt
R
el
at
iv
e 
am
ou
nt
R
el
at
iv
e 
am
ou
nt
R
el
at
iv
e 
am
ou
nt
R
el
at
iv
e 
am
ou
nt
Cyclin E2 – 72 hours
Cyclin D2 – 72 hours
CDK4 – 72 hours
’877
Palbo
–
–
+
–
–
+
+
+
’877
Palbo
–
–
+
–
–
+
+
+
24hrs 48hrs 72hrs
Phospho Rb
(Ser 807-811)
Total Rb
MSC2504877 10μM       - +       - +            - +       - +         - +       - +   
Palbociclib 0.5μM           - - +       +            - - +      +         - - +      +
0
0.5
1
1.5
R
el
at
iv
e 
am
ou
nt
24hrs 48hrs 72hrs
MSC2504877 10 μM
Palbociclib 0.5 μM
–
–
+
–
–
+
+
+
–
–
+
–
–
+
+
+
–
–
+
–
–
+
+
+
Phospho Rb protein levels
E. 
F. 
DMSO MSC2504877 10 µM Palbociclib 0.5 µM
MSC2504877 1 µM
+ Palbociclib 0.5 µM
MSC2504877 10 µM
+ Palbociclib 0.5 µM
DMSO MSC2504877 10 µM Palbociclib 0.5 µM
MSC2504877 1 µM
+ Palbociclib 0.5 µM
MSC2504877 10 µM
+ Palbociclib 0.5 µM
DM
SO
 
Pa
lbo 87
7 
Co
mb
ina
tio
n
0.0
0.5
1.0
1.5
2.0
C
yc
lin
 D
2 
ex
pr
es
si
on
 n
or
m
al
is
ed
 to
 G
A
PD
H
24hrs
p - 0.005
ns
p - 0.0005
*
**
*
*p< 0.005
** p <0.05
MSC2504877 10 μM
Palbociclib 0.5 μM
–
–
–
+
+
–
+
+
N
or
m
al
is
ed
C
C
N
D
2 
m
R
N
A
 le
ve
l
G. 
10 microns
B. C. 
D. E.
F. 
Villin-CreERT2;Apcfl/fl 
mice
Tamoxifen-induced Cre
Homozygous 
deletion of Apc in 
the intestinal 
epithelium
Wnt pathway
Intestinal crypt expansion
Lgr5
p21
1 mm
1 mm
H & E
100 microns
BrdU
100 microns
Lgr5
100 microns
Lgr5
100 microns
Lgr5
100 microns
Lgr5
100 microns
Villin-CreERT2;Apcfl/fl;KRasLSL-G12D/+ mice
Tamoxifen-induced Cre
Homozygous 
deletion of Apc in 
Kras p.G12D 
mutant intestinal 
epithelium
Wnt pathway
Intestinal crypt expansion
H & E
100 microns
BrdU
100 microns
G. 
H. I. 
